Brainstorm Cell Therapeutics Inc at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa (Virtual) Transcript
I am Stacy Lindborg. I'm Executive Vice President and Head of Global Clinical Research at Brainstorm Cell Therapeutics. And I'm pleased to be here today speaking to you on behalf of the company. I'd like to start by introducing you to Brainstorm's unique cell therapy product.
It's an autologous product, which means that we use a patient's own cells to produce their product. As part of the manufacturing, cryopreservation allows us to create an off-the-shelf product for each patient as one harvest of bone marrow creates several years of therapy. From the point of harvesting bone marrow, the first treatment is available in 19 days with subsequent treatments being available in seven days.
Attributes that contribute to the product being consistent and reliable include things like there are no animal proteins or antibiotics, genetic modifications, or viral vectors used. NurOwn is culture-rescued, creating a product with a very high cell viability and consistent performance
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |